GAVI CEO warns patents impeding innovation; EU backs brain cancer vax;

> The CEO of GAVI said strong patent protection and upfront royalty fees are impeding innovation in hepatitis C vaccines. Piece

> The European Union has backed a brain cancer vaccine consortium with $7.7 million. Item (reg. req.)

> An Indian health director has questioned the quality of the vaccine cold chain. Article

> It has been 80 years since a team of British researchers identified the viral cause of flu. Feature

> Police in Pakistan have arrested two people for attacking a polio vaccine worker. News

> The lack of a vaccine is hindering Singapore's efforts to control an outbreak of dengue fever. Item

> Britain is nearing its target vaccination rate for measles after 100,000 people received the MMR jab in the recent outbreak. Article

Suggested Articles

As a new coronavirus spreads, vaccine researchers have started work on candidates against the virus—and one could enter the clinic in a few months.

Merck's HPV vaccine Gardasil is delivering blockbuster sales as demand surges. But high demand has caused somewhat of a supply constraint.

GSK's Shingrix has generated blockbuster sales early in the launch, but there's a lot of remaining opportunity, an exec said at JPM.